(VIANEWS) – EUROFINS SCIENT. (ERF.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| EUROFINS SCIENT. (ERF.PA) | €59.08 | 1.82% | 6.16% |
| UCB (UCB.BR) | €134.30 | 1.05% | 3.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. EUROFINS SCIENT. (ERF.PA)
1.82% Forward Dividend Yield and 6.16% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 6.51B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUROFINS SCIENT.’s stock is considered to be overbought (>=80).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.82%.
Volatility
EUROFINS SCIENT.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.64%, a negative 0.28%, and a positive 1.40%.
EUROFINS SCIENT.’s highest amplitude of average volatility was 0.88% (last week), 1.20% (last month), and 1.40% (last quarter).
More news about EUROFINS SCIENT..
2. UCB (UCB.BR)
1.05% Forward Dividend Yield and 3.8% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.77.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 75.88. Meaning, the purchaser of the share is investing €75.88 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 26, 2024, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 1.05%.
Volume
Today’s last reported volume for UCB is 112451 which is 63.34% below its average volume of 306805.
Yearly Top and Bottom Value
UCB’s stock is valued at €134.30 at 02:30 EST, above its 52-week high of €131.05.
Moving Average
UCB’s value is higher than its 50-day moving average of €122.24 and way above its 200-day moving average of €93.19.
More news about UCB.
